Journal
ALZHEIMERS & DEMENTIA
Volume 12, Issue 1, Pages 60-64Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2015.12.003
Keywords
Alzheimer's; Research & development; Clinical trials; Dementia; Attrition; Amyloid hypothesis
Categories
Funding
- National Institute for Health Research [NF-SI-0513-10134, NF-SI-0508-10123] Funding Source: researchfish
- MRC [MR/L023784/1, MC_U105184291] Funding Source: UKRI
- Medical Research Council [MR/L023784/1, MC_U105184291] Funding Source: Medline
Ask authors/readers for more resources
The success rate of the pharmaceutical research and development (R&D) for dementia drugs has been abysmally low, in the last two decades. Also low has been the number of pipeline drugs in development, compared to other therapy areas. However, the rationale of early terminations has not been reported in the majority of trials. These are key findings of the recently published pharmaceutical pipeline analysis by the UK-based Office of Health Economics (OHE). Our understanding of main challenges include (1) the significant gaps of knowledge in the nosology and complexity of the underpinning biological mechanisms of the commonest, not familial, forms of late onset dementias; (2) low signal-to-noise ratio, notwithstanding the lack of validated biomarkers as entry and/or end-point criteria; (3) recruitment and retention, particularly in the asymptomatic and early disease stages. A number of current and future strategies aimed at ameliorating drug development are outlined and discussed. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available